StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) stock

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$71.06−0.91 (-1.26%)

Close on Nov 17, 2026Market cap $476.97MP/E –Yield –

Monopar Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Monopar Therapeutics's total assets was $134.98M at Jun 30, 2026. For fiscal 2025 it was $140.72M, up 133.4% from the year before. The highest annual figure on record is $140.72M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$140.72M+133.4%
FY2024Dec 31, 2024$60.29M+720.8%
FY2023Dec 31, 2023$7.35M-44.5%
FY2022Dec 31, 2022$13.23M-35.5%
FY2021Dec 31, 2021$20.52M+21.7%
FY2020Dec 31, 2020$16.87M+26.3%
FY2019Dec 31, 2019$13.35M+82.5%
FY2018Dec 31, 2018$7.32M-26.3%
FY2017Dec 31, 2017$9.93M+243.0%
FY2016Dec 31, 2016$2.90M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$134.98M+150.6%
Q1 FY2026Mar 31, 2026$137.98M+150.5%
Q4 FY2025Dec 31, 2025$140.72M+133.4%
Q3 FY2025Sep 30, 2025$144.20M+2275.7%
Q2 FY2025Jun 30, 2025$53.87M+650.2%
Q1 FY2025Mar 31, 2025$55.09M+518.1%
Q4 FY2024Dec 31, 2024$60.29M+720.8%
Q3 FY2024Sep 30, 2024$6.07M-29.4%
Q2 FY2024Jun 30, 2024$7.18M-30.6%
Q1 FY2024Mar 31, 2024$8.91M-24.7%
Q4 FY2023Dec 31, 2023$7.35M-44.5%
Q3 FY2023Sep 30, 2023$8.59M-40.5%
Q2 FY2023Jun 30, 2023$10.34M-38.2%
Q1 FY2023Mar 31, 2023$11.83M-34.5%
Q4 FY2022Dec 31, 2022$13.23M-35.5%
Q3 FY2022Sep 30, 2022$14.45M-35.8%
Q2 FY2022Jun 30, 2022$16.74M-31.6%
Q1 FY2022Mar 31, 2022$18.07M-30.3%
Q4 FY2021Dec 31, 2021$20.52M+21.7%
Q3 FY2021Sep 30, 2021$22.52M+24.0%
Q2 FY2021Jun 30, 2021$24.46M+91.0%
Q1 FY2021Mar 31, 2021$25.91M+101.8%
Q4 FY2020Dec 31, 2020$16.87M+26.3%
Q3 FY2020Sep 30, 2020$18.16M+255.4%
Q2 FY2020Jun 30, 2020$12.80M+128.8%
Q1 FY2020Mar 31, 2020$12.84M+102.1%
Q4 FY2019Dec 31, 2019$13.35M+82.5%
Q3 FY2019Sep 30, 2019$5.11M-35.2%
Q2 FY2019Jun 30, 2019$5.60M-33.8%
Q1 FY2019Mar 31, 2019$6.35M-30.5%
Q4 FY2018Dec 31, 2018$7.32M-26.3%
Q3 FY2018Sep 30, 2018$7.89M+172.4%
Q2 FY2018Jun 30, 2018$8.45M–
Q1 FY2018Mar 31, 2018$9.15M–
Q4 FY2017Dec 31, 2017$9.93M–
Q4 FY2016Dec 31, 2016$2.90M–

More Monopar Therapeutics figures

See a number that looks wrong?